355
Participants
Start Date
June 30, 2008
Primary Completion Date
April 30, 2013
Study Completion Date
April 30, 2013
OMBRABULIN (AVE8062)
I.V. infusion followed by administration of cisplatin
Placebo
I.V. infusion followed by administration of cisplatin
Investigational Site Number 348001, Budapest
Investigational Site Number 056001, Brussels
Investigational Site Number 056005, Liège
Investigational Site Number 348002, Debrecen
Investigational Site Number 056004, Haine-Saint-Paul
Investigational Site Number 891001, Belgrade
Investigational Site Number 250010, Marseille
Investigational Site Number 380002, Rozzano
Investigational Site Number 380003, Milan
Investigational Site Number 380004, Milan
Investigational Site Number 250002, Dijon
Investigational Site Number 891002, Kamenitz
Investigational Site Number 724001, Madrid
Investigational Site Number 724003, Pamplona
Investigational Site Number 840003, Orlando
Investigational Site Number 250008, Bordeaux
Investigational Site Number 380001, Aviano
Investigational Site Number 250006, Montpellier
Investigational Site Number 250005, Rennes
Investigational Site Number 250012, Saint-Priest-en-Jarez
Investigational Site Number 250009, Saint-Herblain
Investigational Site Number 250004, Lille
Investigational Site Number 840005, Maywood
Investigational Site Number 250001, Lyon
Investigational Site Number 840001, San Antonio
Investigational Site Number 840004, Santa Monica
Investigational Site Number 250003, Saint-Cloud
Investigational Site Number 356004, New Delhi
Investigational Site Number 356003, Hyderabad
Investigational Site Number 356005, Bangalore
Investigational Site Number 840002, Newark
Investigational Site Number 840007, Philadelphia
Investigational Site Number 076007, Belo Horizonte
Investigational Site Number 076008, Goiânia
Investigational Site Number 076003, Ijuí
Investigational Site Number 076004, Jaú
Investigational Site Number 076006, Novo Hamburgo
Investigational Site Number 076002, Porto Alegre
Investigational Site Number 076005, Porto Alegre
Investigational Site Number 076009, Rio de Janeiro
Investigational Site Number 250007, Nice
Investigational Site Number 724004, Barcelona
Investigational Site Number 826001, Bebington
Investigational Site Number 826003, Bristol
Investigational Site Number 826002, Newcastle upon Tyne
Lead Sponsor
Sanofi
INDUSTRY